9.33

1.20% 0.10

Neogenomics Inc (NEO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt NEO? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$9.23

Offen:

$9.24

24-Stunden-Volumen:

533.17K

Relative Volume:

0.28

Marktkapitalisierung:

$1.21B

Einnahmen:

$745.97M

Nettoeinkommen (Verlust:

$-99.21M

KGV:

-12.07

EPS:

-0.7729

Netto-Cashflow:

$-5.09M

1W Leistung:

+11.34%

1M Leistung:

+12.68%

6M Leistung:

-22.99%

1J Leistung:

+26.06%

1-Tages-Spanne:

$9.035

$9.36

1-Wochen-Bereich:

$8.34

$9.36

52-Wochen-Spanne:

$4.72

$13.74

Neogenomics Inc Stock (NEO) Company Profile

Firmenname

Neogenomics Inc

Sektor

Healthcare (1110)

Branche

Diagnostics & Research (52)

Telefon

(239) 768-0600

Adresse

9490 NEOGENOMICS WAY, FORT MYERS, FL

Mitarbeiter

2,500

Twitter

@NeoGenomics

Nächster Verdiensttermin

2026-04-28

Neueste SEC-Einreichungen

NEO's Discussions on Twitter

Compare NEO vs TMO, DHR, IDXX, WAT, A

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NEO Neogenomics Inc	9.33	1.20B	745.97M	-99.21M	-5.09M	-0.7729
TMO Thermo Fisher Scientific Inc	448.35	166.59B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	172.85	121.74B	24.78B	3.68B	5.29B	5.1743
IDXX Idexx Laboratories Inc	557.99	44.12B	4.45B	1.10B	1.06B	13.59
WAT Waters Corp	339.37	33.62B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	115.50	32.49B	7.07B	1.29B	993.00M	4.5355

Neogenomics Inc Stock (NEO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-07-30	Herabstufung	BTIG Research	Buy → Neutral
2025-07-29	Herabstufung	William Blair	Outperform → Mkt Perform
2025-05-15	Eingeleitet	Guggenheim	Neutral
2025-04-30	Herabstufung	Leerink Partners	Outperform → Market Perform
2025-01-13	Herabstufung	The Benchmark Company	Buy → Hold
2024-12-10	Eingeleitet	Jefferies	Buy
2024-05-01	Fortgesetzt	Craig Hallum	Buy
2023-12-29	Bestätigt	BTIG Research	Buy
2023-08-21	Hochstufung	Stephens	Equal-Weight → Overweight
2023-05-16	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-05-09	Hochstufung	BTIG Research	Neutral → Buy
2023-02-24	Hochstufung	The Benchmark Company	Hold → Buy
2023-02-01	Hochstufung	Needham	Hold → Buy
2022-08-26	Herabstufung	The Benchmark Company	Buy → Hold
2022-08-22	Herabstufung	Needham	Buy → Hold
2022-06-03	Eingeleitet	Piper Sandler	Overweight
2022-03-29	Herabstufung	BofA Securities	Buy → Neutral
2022-03-29	Herabstufung	Stephens	Overweight → Equal-Weight
2022-01-18	Fortgesetzt	Stephens	Overweight
2021-12-16	Eingeleitet	Cowen	Outperform
2021-11-05	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-10-14	Hochstufung	Raymond James	Mkt Perform → Outperform
2021-06-03	Eingeleitet	Goldman	Buy
2021-02-25	Fortgesetzt	Needham	Buy
2021-02-25	Herabstufung	Raymond James	Outperform → Mkt Perform
2021-01-28	Eingeleitet	Truist	Buy
2020-12-11	Fortgesetzt	BTIG Research	Buy
2020-10-28	Bestätigt	Needham	Buy
2020-09-09	Eingeleitet	Morgan Stanley	Overweight
2020-08-28	Eingeleitet	Guggenheim	Buy
2020-07-29	Bestätigt	Needham	Buy
2020-06-25	Eingeleitet	BofA/Merrill	Buy
2020-04-21	Fortgesetzt	Stephens	Overweight
2020-03-02	Fortgesetzt	Craig Hallum	Buy
2020-02-28	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2020-01-23	Herabstufung	First Analysis Sec	Strong Buy → Outperform
2019-10-30	Bestätigt	Needham	Buy
2019-05-01	Bestätigt	Needham	Buy
2019-03-29	Bestätigt	Needham	Buy
2019-01-03	Eingeleitet	Needham	Buy
2018-10-24	Hochstufung	First Analysis Sec	Outperform → Strong Buy
2018-08-21	Eingeleitet	Leerink Partners	Outperform
2018-05-02	Herabstufung	First Analysis Sec	Overweight → Equal-Weight
2017-09-11	Herabstufung	BTIG Research	Buy → Neutral
2017-08-24	Eingeleitet	Gabelli & Co	Buy
2016-12-15	Eingeleitet	Cantor Fitzgerald	Overweight

Alle ansehen

Neogenomics Inc Aktie (NEO) Neueste Nachrichten

07:05 AM

NeoGenomics to Present New Research at ASCO Annual Meeting 2026 - Business Wire

07:05 AM

May 25, 2026

(NEO) Risk Channels and Responsive Allocation - Stock Traders Daily

May 25, 2026

May 22, 2026

A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $11 to $25 - Moomoo

May 22, 2026

Shareholders approve NeoGenomics (NASDAQ: NEO) equity plan amendment and board slate - Stock Titan

May 22, 2026

May 20, 2026

NeoGenomics Earnings Call Highlights NGS-Driven Momentum - TipRanks

May 20, 2026

May 19, 2026

NeoGenomics stock (US64049M2098): Q1 update keeps focus on cancer testing demand - AD HOC NEWS

May 19, 2026

May 17, 2026

NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know - Yahoo Finance

May 17, 2026

May 15, 2026

NEOGENOMICS (NEO) 13G/A: Greenhouse reports 9,215,903 shares (7.1%) - Stock Titan

May 15, 2026

NeoGenomics signals $797M-$803M 2026 revenue outlook following PanTracer Liquid MolDX approval - MSN

May 15, 2026

Oncology diagnostics group NeoGenomics meets investors at May, June conferences - Stock Titan

May 15, 2026

Millennium group reports 2.22M NEO shares (1.7%) — Joint filing (NEO) - Stock Titan

May 13, 2026

NeoGenomics (NEO) EVP adds shares via RSU vesting while covering taxes - Stock Titan

May 13, 2026

NeoGenomics (NEO) COO exercises RSUs, withholds shares for taxes and holds 164,032 shares - Stock Titan

May 13, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

Is NeoGenomics’ Higher 2026 Revenue Outlook And Narrower Loss Profile Altering The Investment Case For NEO? - Sahm

May 11, 2026

May 09, 2026

NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

May 09, 2026

May 08, 2026